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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of pharmacological and psychological continuation and maintenance treatments for persistent depressive disorder,
in comparison with each other; placebo (drug/attention placebo/non-specific treatment control); and treatment as usual (TAU). In
addition, to assess the effects of combined psychological and pharmacological continuation and maintenance treatments, in comparison
with either of these treatments alone.
B A C K G R O U N D
Description of the condition
Persistent forms of depression that last for two years or longer
represent a substantial proportion of depressive disorders (Boland
2002; Gilmer 2005; Keller 1992; Spijker 2002). Within the lit-
erature, four subtypes can be distinguished: (1) dysthymia, (2)
chronic major depression, (3) recurrent major depression with in-
complete remission between episodes, and (4) double depression
(Dunner 2005). Dysthymic disorder is defined as a condition with
mild depressive symptoms persisting for at least two years. Major
depressive episode, chronic type, refers to a more severe condition
that meets the full criteria for major depression continuously for a
minimum of two years. Patients who have recovered to the point
at which they no longer meet full criteria for a major depressive
episode but continue to experience significant symptoms for at
least two years are referred to as recurrent major depression with
incomplete remission between episodes. The superimposition of a
major depressive episode on antecedent dysthymia is referred to as
double depression (Klein 2010). In the Diagnostic and Statistical
Manual of Mental Disorders (DSM)-5 (APA 2013), the new di-
agnostic category of persistent depressive disorder was introduced
subsuming dysthymic as well as chronic major depressive disor-
ders.
The mean length of persistent depression is between 17 to 30
years (Gilmer 2005; Kocsis 2008), and the lifetime prevalence for
persistent depressive disorders is estimated to range from 3% to
6% in current epidemiological studies from the US and Australia
(Kessler 2005; Klein 2010; Murphy 2012). In comparison to acute
forms of depression, persistent depressive disorders are associated
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with longer treatment duration; increased loss of physical well-
being; increased comorbidity; more severe impairments in social,
psychological, and emotional functioning; increased health care
utilization; and more frequent suicide attempts and hospitaliza-
tions (Arnow 2003; Gilmer 2005). Thus, persistent depression is
likely to make a large contribution to the high burden of disease
that is associated with unipolar depression according to disability-
adjusted life years (DALYs) (WHO 2008).
Description of the intervention
Overall, a large number of different interventions exist for the
treatment of unipolar depression, including psychological, phar-
macological, and combined psychological and pharmacological
therapies. Evidence from randomized controlled trials (RCTs), as
well as meta-analyses, suggests that these interventions are effective
in the acute treatment of depression, including persistent forms
of depression (Cuijpers 2010; Cuijpers 2013; Imel 2008; Keller
2000; Kriston 2014; Spijker 2013; von Wolff 2012; von Wolff
2013). Still, there is also evidence that some patients do not re-
spond to treatment, do not reach complete remission, and develop
persisting residual symptoms in the long term (Epstein 2014). It
is estimated that half of the people suffering from depressive dis-
orders are developing a chronic course (Klein 2011).
Moreover, acute phase treatments often fail to prevent relapse
(which is defined as the return of symptoms of depression before a
full remission has been achieved) and recurrence (which is defined
as the appearance of another new episode of depression after full
remission of a previous episode has been achieved) in major de-
pression. For example, after scheduled termination of acute phase
cognitive therapy (CT), relapse or recurrence rates were found to
be 29% in the first year and 54% in the second year (Vittengl
2007). In this same study, even when other depression-specific
psychological therapies and even higher doses of pharmacotherapy
were used after the acute-phase treatment, relapse and recurrence
rates were still high (Vittengl 2007). One study has shown that
30% to 50% of patients considered to be remitted still have to
deal with residual depressive symptoms (Nutt 2007).
Thus, following response to acute treatment, long-term contin-
uation and maintenance therapy is required to protect patients
from relapse or recurrence of symptoms. Continuation treatments
are defined as treatments given to currently remitted patients (re-
mission is defined as depressive symptoms dropping below case
level) or to patients that previously responded to an antidepressant
treatment. Maintenance therapy is given during recovery (which
is defined as remission lasting longer than six months; Frank 1991;
NICE 2010). The German National Disease Management Guide-
line (S3-Guideline) for Unipolar Depression recommends a com-
bination of pharmacotherapy and psychological therapy as acute
phase treatment for patients suffering from persistent forms of de-
pression (DGPPN 2015). Additionally, a continued psychological
therapy or pharmacotherapy, or both, is recommended to prevent
relapse and recurrence. Specifically, the type of treatment that was
successful in the acute phase is recommended to be continued
(APA 2010; DGPPN 2015; NICE 2010).
However, these recommendations are based on a limited number
of studies and expert opinion. Hence, a systematic search of evi-
dence regarding the effectiveness of pharmacological, psycholog-
ical, and combined pharmacological and psychological therapies
as continuation and maintenance treatments for patients suffering
from persistent forms of depression is needed.
How the intervention might work
Acute treatments aim to reduce depressive symptoms and re-estab-
lish psychosocial functioning. In comparison, continuation and
maintenance treatments aim to maintain (or improve) the psycho-
functional status reached by acute treatment, and to reduce the
likelihood of relapse and recurrence in the long-term (DGPPN
2015). Therefore, continuation and maintenance treatments are
considered to be more than a pure extension of acute treatments,
because continuation/maintenance treatments differ in frequency
and content over the course of the illness in comparison to acute
treatments.
Psychological continuation and maintenance interventions are of-
fered usually less frequently than acute psychological therapy, aim-
ing to monitor symptoms and to integrate techniques and strate-
gies into daily life in the long-term (DGPPN 2015). Different
programmes that target the prevention of relapse and recurrence
focus on a range of effect mechanisms. Cognitive therapy (CT) ap-
proaches focus on the generalization of skills achieved during acute
therapy (Jarrett 1998), or on the cognitive content of negative
thinking (Bockting 2005). Mindfulness-Based Cognitive Therapy
(MBCT) was developed to reduce relapse and recurrence in de-
pression (Piet 2011; Segal 2002), and teaches people to deal with
negative feelings and thoughts as a part of their lives through be-
coming aware of negative cognitive patterns. Maintenance Inter-
personal Psychotherapy (IPT) aims to complement skills gained
in the acute phase therapy and teaches patients to take responsi-
bility in the prevention of future episodes by recognizing and pre-
venting stressing environmental and social circumstances (Beshai
2011). Still, it remains challenging to completely understand the
mechanisms of preventing relapse and recurrence (Beshai 2011).
The exact therapeutic mechanisms of antidepressants are still crit-
ically discussed (Pringle 2011). Most antidepressants seem to in-
crease the concentrations of monoamine neurotransmitters (e.g.
serotonin or noradrenaline) in the synaptic cleft (Berton 2006).
However, the effect of most antidepressants fully develops after
some weeks, indicating that neurophysiological changes of brain
tissue (e.g. changes in sensitivity and frequency of receptors), oc-
curring in the presence of a constant level of active ingredients, are
necessary for permanent improvement. Depending on the type of
active ingredient, antidepressants can have mood-enhancing, anx-
iolytic, or sedative effects and can increase or decrease inner drive.
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Moreover, the placebo effect is of particular importance in the
treatment of depression. Several studies assume that the more se-
vere the depressive symptoms are, the greater the benefit of antide-
pressants seem to be compared to placebo (Anderson 2008; Kirsch
2008). However, a recent meta-analysis performed on patient-level
data regarding the response to antidepressant medication showed
that initial depression severity and outcomes were similarly related
in treatment and placebo groups (Rabinowitz 2016).
A number of studies have shown that the risk of relapse or recur-
rence of depression is associated with residual symptoms following
acute treatment phases (APA 2010; NICE 2010). These findings
have lead to the therapeutic goal of sustained remission and rec-
ommendations of international treatment guidelines to continue
antidepressant medication after acute phase treatment (APA 2010;
NICE 2010).
Why it is important to do this review
Research that focuses on the prevention of recurrence of depres-
sion was identified as a top priority in the recent project ’Depres-
sion: asking the right questions’ (MQ 2016). The high prevalence
and the severe personal, societal, and economic consequences of
persistent depressive disorder (Gilmer 2005), underline the need
for adequate treatment strategies. Growing evidence indicates that
persistent depressive disorder responds well to several acute in-
terventions, such as combined psychological and pharmacological
treatments, although the number of RCTs is still limited (Spijker
2013). Yet, given the high rates of relapse and recurrences of de-
pression following response to acute treatment, long-term contin-
uation and maintenance therapy are of great importance (Beshai
2011).
Several RCTs have supported the effectiveness of continuation
and maintenance therapies for depression has been supported
(Browne 2002; Jarrett 2001; Jarrett 2013; Keller2007; Klein 2004;
Petersen 2010; Vittengl 2009). A meta-analysis on relapse pre-
vention with antidepressant drug treatment of depressive disor-
ders showed that continued antidepressant medication produced
a robust reduction in relapse (Glue 2010). Another meta-analy-
sis, Vittengl 2007, summarizes the findings of long-term effects of
cognitive behavioural therapy (CBT). Patients who responded to
acute treatment and continued to receive CBT showed a signif-
icant reduction in relapse and recurrence rates in comparison to
inactive as well as active controls.
Although most evidence addresses acute treatments for persistent
depressive disorder or long-term treatments for acute depressive
episodes, some studies have been performed to address the effec-
tiveness of long-term treatments of persistent depressive disorder
(Gelenberg 2003; Harrison 1986; Keller 1998; Klein 2004; Kocsis
1996; Kocsis 2003; Koran 2001; Rouillon 1989; Stangier 2013).
Until now, no systematic review on the comparative effectiveness of
continuation and maintenance treatments for persistent depressive
disorder has been available.
In summary, this systematic review may be highly relevant as:
• persistent depressive disorders have a high prevalence and
serious personal, societal, and economic consequences;
• no evidence synthesis is available on continuation and
maintenance treatments of persistent depressive disorders;
• high quality evidence synthesis is needed for clinical
guideline recommendations.
O B J E C T I V E S
To assess the effects of pharmacological and psychological con-
tinuation and maintenance treatments for persistent depressive
disorder, in comparison with each other; placebo (drug/attention
placebo/non-specific treatment control); and treatment as usual
(TAU). In addition, to assess the effects of combined psychological
and pharmacological continuation and maintenance treatments,
in comparison with either of these treatments alone.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs, including cross-over and cluster-RCTs, and
controlled clinical trials (CCTs). We have considered CCTs for
inclusion as the number of RCTs may be limited. We will not
apply any restrictions regarding other study design characteristics.
Types of participants
Participant characteristics
We will include participants 18 years of age and older of any gender
and ethnicity.
Diagnosis
We will include participants who have a diagnosis of persistent
depressive disorder or have had this diagnosis before their last pre-
vious acute treatment. The diagnosis of depression needs to rely
on a formal classification system, such as the International Classi-
fication of Diseases (ICD) (WHO 1992), or DSM (APA 2013).
Participants need to be either currently remitted from persistent
depressive disorder or need to have at least partially responded to
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an acute intervention (at least 25% symptom reduction from base-
line) at the beginning of the continuation or maintenance treat-
ment. We will include participants described as “treatment resis-
tant” if they fulfil the formerly mentioned criteria. As the distinc-
tion between subtypes of persistent depressive disorder (chronic
major depression, dysthymia, double depression, or recurrent de-
pression without a complete remission between episodes) is con-
troversial, inclusion will be primarily driven by the duration of the
existing depressive disorder. Consequently, we will include studies
that investigate participants with chronic major depression, dys-
thymia, double depression, or recurrent depression without a com-
plete remission between episodes if the target disorders are or have
been of at least two years’ duration. We will exclude studies that
report to investigate “chronically depressed” participants without
fulfilling these criteria (e.g. less than two years duration).
Co-morbidities
We will exclude studies that focus exclusively on persistently de-
pressed participants with a specific concurrent mental or somatic
disorder; we assume that the interventions in these types of studies
(primarily) address the comorbid condition and are not focused
exclusively on persistent depression. We will include studies that
do not define specific concurrent mental or somatic conditions as
inclusion criteria but report on comorbidities in addition to the
persistent depressive disorder.
Setting
We will not place any restrictions based on setting.
Subset data
We will only consider studies in which both participants with
persistent and acute forms of depression for inclusion if data are
reported separately for the persistent subgroup (or if 80% or more
of the total sample has a diagnosis of persistent depression). If
randomization is based on the total sample, we will include studies
and we will categorize them as non-RCTs.
Types of interventions
Experimental Intervention
We will consider pharmacological, psychological, and combined
continuation and maintenance interventions for inclusion. Con-
tinuation treatments are defined as treatments given to currently
remitted individuals or to individuals that previously responded
to an antidepressant treatment, whereas maintenance treatments
are defined as treatments given to people who are currently re-
covered. Continuation/maintenance treatments need to be started
within one year after termination of an acute treatment. We will
consider all interventions that satisfy these definitions. Addition-
ally, we will consider for inclusion studies that do not report all
the above mentioned criteria but report data on interventions that
are clearly labelled as “continuation” or “maintenance” treatments.
Pharmacological interventions include the oral administration of
classified antidepressants:
• tricyclic antidepressants;
• selective serotonin reuptake inhibitors;
• monoamine oxidase inhibitors;
• alpha2-receptor-antagonists;
• selective noradrenalin dopamine reuptake inhibitors;
• melatonin receptor agonists; and
• serotonin 5 HT2C receptor antagonists;
as well as the following:
• non-classified antidepressants (Trazodone);
• lithium;
• Hypericum perforatum; and
• antipsychotic drugs;
as these drugs can be used (alone or in combination) in treating
different forms of depression (DGPPN 2015).
Psychological therapies must fulfil the following criteria:
• the intervention must be based on a scientific theory
(described in detail, manualized or referenced);
• at least one contact between therapist and participant either
face-to-face or via telecommunication technologies (e.g. online
therapy) must take place. Thus, for example, we will not
consider the general dissemination of information material in
form of leaflets in waiting rooms as a psychological therapy;
• the intervention must consider the personal needs of the
participant or a group of participants and must be individually
tailored in an interpersonal process. Thus, we will include group
therapies.
Concerning psychological therapies, we will include behaviour
therapy/behaviour modification, CBT, third wave CBTs, psycho-
dynamic therapies, humanistic therapies, integrative therapies, sys-
temic therapies, and other psychologically-oriented interventions
(based on the definition of the Cochrane Common Mental Dis-
orders Group).
Combined interventions include the administration of one or
more pharmacological agents combined with one or more psycho-
logical therapy.
We will not consider for inclusion somatic (e.g. electroconvul-
sive therapy, vagus nerve stimulation, acupuncture), non-pharma-
cological (e.g. physical exercise, bright light therapy), and orga-
nizational (e.g. case management) interventions as including too
many different interventions is likely to result in large clinical and
methodological heterogeneity.
Comparator intervention
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We will include both controlled and comparative effectiveness
studies. The comparators may be:
• pharmacological placebo (participants receive placebo pills);
• attention-placebo/nonspecific control (participants receive a
treatment that involves nonspecific psychosocial factors);
• TAU;
• (other) psychological therapy;
• (other) pharmacological treatment;
• (other) combined psychological/pharmacological therapy.
Types of outcome measures
Primary outcomes
• Relapse or recurrence rate of depression, preferentially
defined as:
(a) fulfilment of formal diagnostic criteria for depression (DSM,
ICD); or
(b) exceeding a cut-off on a depression symptom rating scale used
by the authors, specifically:
i. the Hamilton Depression Rating Scale (HDRS) (Hamilton
1960);
ii.the Montgomery -Åsberg Depression Rating Scale (MADRS)
(Montgomery 1979);
iii.the Beck-Depression-Inventory (BDI) (Beck 1996);
iv.the Inventory of Depressive Symptomatology (IDS) (Rush
2000);
v. the Patient Health Questionnaire (PHQ) (Spitzer 1999); or
vi.any other depression symptom scale.
Due to the long tradition of depression research, most instruments
used in clinical trials are usually psychometrically sound. Such
measures will be preferred throughout the review (either referenced
and/or sufficient psychometric quality reported).
• Dropout due to any reason.
Secondary outcomes
• Symptom severity of depression at the end of treatment
(metric outcome of depression scale as defined above);
• health-related quality of life e.g. WHO Quality of Life
(WHOQOL) (Skevington 2004);
• dropout due to adverse events;
• experiencing any adverse event;
• serious adverse events.
Timing of outcome assessment
The primary outcome time point will be the ‘end of intervention’
(regardless of the duration of the intervention). Additionally, we
will evaluate outcomes at the time point ‘one year after the end
of intervention’ provided sufficient data are available. If one-year
data are unavailable, we will use data that range between six and
18 months after the end of intervention, with a preference for the
time that was closest to one year after the end of intervention.
Hierarchy of outcome measures
If more than one diagnostic definition or depression symptom
rating scale, or both, are available (concerning the outcome ’Re-
lapse or recurrence rate of depression’), we will use the presented
hierarchy to select measures (priority starting with (a) fulfilment
of formal diagnostic criteria, continuing with (b) (i. HDRS), (ii.
MADRS) etc.).
Search methods for identification of studies
Electronic searches
• The Cochrane Common Mental Disorders Group
maintains a specialized register of RCTs: the CCMD-CTR
(description in Appendix 1).
We will search the CCMD-CTR for study records using the fol-
lowing controlled search terms (condition only):
(“chronic depression” or “dysthymia” or “dysthymic disorder” or
“persistent depressive disorder” or “recurrent depression”)
• We will search the CCMD-CTR for reference records using
a more sensitive set of terms (condition only):
(“chronic* depress*” or “double depress*” or dysthymi* or
(depress* NEAR2 recurr*) or “persistent depressive disorder”):
ti,ab,kw,ky,mh,mc,emt
[Key: ti=title; ab=abstract; kw=keywords; ky=additional keywords;
mh=MeSH terms; mc=MeSH checkwords;emt=EMTREE terms]
We will screen records for continuation and maintenance trials.
• As the review will include both RCTs and CCTs, we will
conduct complementary searches on the following bibliographic
databases using relevant subject headings and search syntax’,
appropriate to each resource:
◦ OVID PsycINFO (search strategy listed in Appendix
1);
◦ PSYNDEX;
◦ OVID MEDLINE, Embase, PsycINFO (cross-search);
◦ the Cochrane Library.
We will search databases from 1970 onwards (Embase from 1980);
and we will not apply any other restriction on language or publi-
cation status to the searches.
We will screen records retrieved from the CCMD-CTR and
PsycINFO searches prior to running other database searches. We
will validate the search strategies to prevent the retrieval of too
many irrelevant references (e.g. whether it is appropriate to include
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We will search the following sources of grey literature:
• ProQuest Dissertations & Theses Database (
www.proquest.com/);
• Depression. The treatment and management of depression
in adults (NICE 2010);
• S3 Guideline/National Disease Management Guideline.
Unipolar Depression (DGPPN 2015);
• Canadian Network for Mood and Anxiety Treatments
(CANMAT). Clinical guidelines for the management of major
depressive disorder in adults (Kennedy 2009)
• Open Grey (www.opengrey.eu/).
Handsearching
As all relevant journals are included in the bibliographic databases
being searched, we will not conduct any no further handsearches
of journals.
Reference lists
We will check the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches (e.g. unpublished or in-press citations).
Also we will conduct a cited reference search on the Web of Science.
Correspondence
We will contact the first author of each included study for informa-
tion on unpublished or ongoing studies, or to request additional
trial data.
Data collection and analysis
Selection of studies
Two review authors (KM, SL) will independently screen titles and
abstracts for inclusion of all the potential studies identified as a
result of the search and code them as either ’retrieve’ (eligible or
potentially eligible/unclear) or ’do not retrieve’ (ineligible). We
will retrieve the full-text study reports/publications and two review
authors (KM, SL, or RM) will independently screen the full-texts
and determine studies for inclusion. We will record the reasons for
exclusion of the ineligible studies. We will resolve any disagreement
through discussion or, if required, we will consult a fourth review
author (AJ). We will identify and exclude duplicate records and
will collate multiple reports that relate to the same study so that
each study, rather than each report, is the unit of interest in the
review. We will record the selection process in sufficient detail
to complete a PRISMA flow diagram and a ‘Characteristics of
excluded studies’ table.
Data extraction and management
We will use a data collection form, which has been piloted on at
least one study in the review, to extract study characteristics and
outcome data. Two review authors (KM, SL, or RM) will inde-
pendently extract study characteristics and outcome data from in-
cluded studies. We will extract the following study characteristics:
• methods: study design, time of randomization, total
duration of study, location, study setting, and date of study
(year);
• participants: number of participants (N), mean age, age
range, % female, diagnostic subgroup, mean age of onset, length
of current/last episode, number of previous episodes;
• interventions: intervention, comparison, type of acute
treatment previous to continuation/maintenance treatment;
• outcomes: primary and secondary outcomes specified and
collected, and time points reported;
• notes: funding of the trial.
We will note in the ’Characteristics of included studies’ table if
outcome data was not reported in a usable way. We will resolve
disagreements by consensus or by involving a third review author
(KM, SL, or RM). One review author (KM) will transfer data into
Review Manager 5 (RevMan 5) (RevMan 2014). We will double-
check that data is entered correctly by comparing the data pre-
sented in the systematic review with the study reports. A second
review author (SL) will spot-check study characteristics for accu-
racy against the trial report.
Main comparisons
We have chosen seven main comparisons from the list of possible
comparisons based on clinical importance and expected frequency
of the comparisons in clinical trials:
• pharmacological continuation and maintenance therapies
versus placebo;
• pharmacological continuation and maintenance therapies
versus TAU;
• psychological continuation and maintenance therapies
versus attention placebo/nonspecific control;
• psychological continuation and maintenance therapies
versus TAU;
• psychological continuation and maintenance therapies
versus pharmacological continuation and maintenance therapies;
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• combined psychological and pharmacological continuation
and maintenance therapies versus pharmacological continuation
and maintenance therapies alone;
• combined psychological and pharmacological continuation
and maintenance therapies versus psychotherapeutic
continuation and maintenance therapies alone.
Assessment of risk of bias in included studies
Two review authors (KM, SL, or RM) will independently assess
the risk of bias for each included study using the criteria outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). We will resolve any disagreements by discussion
or by involving another review author (KM, SL, or RM). We will
assess the risk of bias according to the following domains:
• random sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other bias.
We will judge each potential source of bias as either at high, low, or
unclear risk of bias and will provide a supporting quotation from
the study report together with a justification for our judgment
in the ’Risk of bias’ table. We will summarize the ’Risk of bias’
judgments across different studies for each of the domains listed.
Where information on risk of bias relates to unpublished data or
correspondence with a trial author, we will note this in the ’Risk
of bias’ table.
We will use the ACROBAT-NRSI tool for assessing the quality
of non-randomized studies in meta-analyses to assess the quality
of non-RCTs (Sterne 2014). Moreover, we will assess recruitment
bias, baseline imbalance, loss of clusters, incorrect analysis, and
comparability with individually randomized trials in cluster-RCTs
(Higgins 2011).
The risk of bias will be considered in sensitivity analyses. Moreover,
we will take the risk of bias into account when we interpret the
treatment effects.
Measures of treatment effect
Dichotomous data
In order to increase clinical applicability of the findings, we will
calculate the relative risk of relapse/recurrence for the primary
outcomes, as they are more likely to help clinicians to make in-
formed decisions in specific clinical situations. If primary studies
used time-to-event data, we will calculate pooled hazard ratios.
For rare outcomes (adverse events, and possibly dropout rates) or
endpoints with highly varying baseline rates, we will estimate the
odds ratios.
Continuous data
We will analyse continuous data as mean differences (MD). If the
included studies used different rating scales to assess the same out-
come, we will calculate the standardized mean differences (SMD).
We will enter data presented as a scale with a consistent direc-
tion of effect. We will undertake meta-analyses only where this
is meaningful, i.e. if the treatments, participants, and the under-
lying clinical question are similar enough for useful pooling. We
will narratively describe skewed data reported as medians and in-
terquartile ranges if effect size calculation is not possible.
Unit of analysis issues
Cluster-randomized trials
As we expect a small number of overall available studies, we will
include data from controlled clinical trials, cross-over trials, and
cluster-randomized trials in the analysis, regardless of the level of
randomization. Concerning cluster-randomized trials, we will in-
clude direct effect estimates of the primary studies, only if they
were obtained from analyses that account for the clustering in the
data (e.g. using a multilevel model). Otherwise, we will approxi-
mate the effect estimates using an inflated standard error that in-
corporates the design effect (Higgins 2011).
Cross-over trials
We will only use the first comparison (pre-crossover) meeting our
inclusion criteria from cross-over trials.
Studies with multiple treatment groups
Concerning studies with multiple treatment groups, we will only
consider data from the comparison of interest for each of the main
objectives addressed in our review. If the study provides more than
one comparison of interest for one of the main objectives, we
will split the ‘shared’ group into two or more groups with smaller
sample sizes to avoid including participants more than once in the
analysis.
Dealing with missing data
In case of missing or unclear data, we will contact correspond-
ing study authors or study sponsors in order to obtain key study
characteristics and missing numerical outcome data when possible
(e.g. when a study is identified as abstract only). We will document
all requests and correspondences.
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For all studies, we will calculate effect sizes using the intention-to-
treat (ITT) principle, i.e. analysing all participants allocated to the
respective study arm. For the primary outcome, we will include
all randomized participants in the analyses irrespective of how the
study authors defined their ITT sample. For all other outcomes
we will follow the definition of the ITT sample provided by the
study authors.
Assessment of heterogeneity
We will test statistical heterogeneity between study results for sig-
nificance using Cochran’s Q-test and will quantify it using the I²
statistic (Higgins 2003).
We will display results visually as forest plots. We expect consider-
able clinical heterogeneity between studies. We will consider the
I² statistic values as follows:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: considerable heterogeneity.
Based on this classification, we will consider I² statistic values in
the range of 50 to 100% as relevant statistical heterogeneity that is
to be further explored. As “thresholds for the interpretation of I²
can be misleading, since the importance of inconsistency depends
on several factors” (Higgins 2011), this is only a rough orientation.
Therefore, we will decide on a case-by-case-basis if the determined
heterogeneity needs to be further explored.
Assessment of reporting biases
We will test possible reporting biases and small-study effects using
visual examination of funnel plots and applying Egger’s test (Sterne
2001).
Data synthesis
We will perform all analyses by applying a random-effects model
(DerSimonian 1986).
We plan to use random-effects models rather than fixed-effect
ones, because we assume that the included studies will not be func-
tionally equivalent and will show considerable clinical (concerning
population, intervention) and methodological (concerning qual-
ity) heterogeneity. We will display results visually as forest plots.
If it will not be possible to combine studies via meta-analysis, we
will provide a narrative summary.
Subgroup analysis and investigation of heterogeneity
In order to identify possible treatment effect moderators, we will
perform a priori defined subgroup analyses (in case of categorical
predictors) or meta-regression analyses (in case of metric predic-
tors) for the primary outcomes. We will test differences between
subgroups formally (Bucher 1997; Deeks 2008; Song 2003). All
meta-regression analyses will be performed using the restricted
maximum likelihood estimate method, a recommended random-
effects approach that accounts for residual between-trial hetero-
geneity (Thompson 1999).
We will consider the following variables:
• subtype of persistent depressive disorder (dysthymia
versus other): a possibly moderating effect of subtype would
suggest that a distinction between these subtypes might be used
for allocation of patients to treatments (differential indication).
On the other hand, a possible homogeneity of effects across
subtypes may suggest that a distinction is of little relevance in the
day-to-day practice. We will test dysthymia against other
subtypes as dysthymia is assumed to be the most frequently
mentioned subtype;
• mean age of onset: the age of onset is known as a relevant
predictor, it should be assessed if patients with early onset need
different treatments;
• applied intervention (cognitive behavioral therapies versus
other, selective serotonin reuptake inhibitors (SSRIs) versus
other): as experience shows, cognitive behavioral approaches/
SSRIs are the most frequent forms of psychological therapies/
antidepressants to be studied. Therefore, we decided to test these
approaches versus other approaches. Evidence on the best
available treatments (in case of considerable differences) is
indispensable for guideline recommendations;
• duration of continuation/maintenance treatment
(weeks): for guideline recommendations and clinical practice, it
is indispensable to know if different treatment durations result in
different outcomes, e.g. if longer treatments lead to better
outcomes.
In case of considerable heterogeneity between study results that we
cannot explain by the a priori defined subgroup and meta-regres-
sion analyses, we will perform a series of a posteriori (explorative)
meta-regression analyses to identify sources of heterogeneity. We
will clearly label a priori and a posteriori analyses as such.
Sensitivity analysis
We will perform sensitivity analyses by excluding studies with a
high or unclear risk of bias (separately for each of the seven domains
according to the Cochrane ’Risk of bias’ tool) or outlying findings,
or both. We will compare results to those acquired with data from
all studies in order to control for possible effects of study quality
on pooled effects.
We will perform the following additional sensitivity analyses:
• excluding trials without a randomization on person level
(second phases of cross-over trials, CCTs, and cluster-
randomized trials); and
• excluding trials without (re-)randomization immediately
before the continuation/maintenance phase in order to control
for possible design effects.
8Continuation and maintenance treatments for persistent depressive disorder (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
’Summary of findings’ table
We will construct ’Summary of findings’ tables for the seven main
comparisons: effectiveness of pharmacotherapy and effectiveness
of psychological therapy for persistent depressive disorder, the ef-
fectiveness of psychological therapy in comparison to pharma-
cotherapy for persistent depressive disorder, and the effectiveness
of combined treatments in comparison to pure pharmacological/
pure psychological therapies for persistent depressive disorder. The
’Summary of findings’ tables will include a summary of the quality
of evidence, the magnitude of effects of the according interven-
tion, and a summary of available data on main outcomes. We will
express findings as measures of risk ratio and absolute risk for the
main outcomes of relapse/recurrence and dropout. We will use the
GRADE approach to assess the quality of the evidence (Guyatt
2011).
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A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Common Mental Disorders Specialized Register (CCMD-CTR)
The Cochrane Common Mental Disorders Group maintains a specialized register of RCTs: the CCMD-CTR. This register contains
over 39,000 reference records (reports of RCTs) for depression, anxiety, and other common mental disorders. A percentage of the
reference records have been tagged to 12,500 individual, PICO-coded (PICO = participants, interventions, comparators, outcomes)
study records (with coding based on the EU-Psi coding manual). Reports of trials for inclusion in the register are collated from (weekly)
generic searches of MEDLINE, Embase, and PsycINFO; quarterly searches of the Cochrane Central Register of Controlled Trials
(CENTRAL); and review-specific searches of additional databases. Reports of trials are also sourced from international trial registries,
drug companies, the handsearching of key journals, conference proceedings, and other (non-Cochrane) systematic reviews and meta-






4. MAJOR DEPRESSION/ and (“CHRONICITY (Disorders)”/ or CHRONIC ILLNESS/)
5. (dysthymi*).ti,ab,id.
6. RECURRENT DEPRESSION/
7. (depress* adj2 recurr*).ti,ab,id.




11. (maintenance or maintained).ti,ab,id.
12. continuation.ti,ab,id.





17. exp EXPERIMENTAL DESIGN/
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18. TREATMENT EFFECTIVENESS EVALUATION/
19. MENTAL HEALTH PROGRAM EVALUATION/
20. (empirical study or longitudinal study or prospective study or quantitative study).md.
21. “2000”.md. [treatment outcome/clinical study]
22. RETROSPECTIVE STUDIES/
23. EVIDENCE BASED PRACTICE/
24. (study or trial or treatment* or intervention or therap* or psychotherap*).ti.
25. (control* adj3 (group*1 or study or trial)).ti,ab,id.
26. (waitlist* or wait list* or treatment* as usual or TAU or care as usual or standard care or standard treatment*).ti,ab,id.
27. placebo.ti,ab,id.
28. PLACEBO/
29. (RCT or random*).ti,ab,id.
30. (crossover* or cross over*).ti,ab,id.
31. (quasi experimental).ti,ab,id.
32. (longitudinal or cohort).ti,ab,id.
33. (case adj (control or report or series)).ti,ab,id.
34. (cross-sectional).ti,ab,id.
35. (experimental or quantitative or pilot).ti,ab,id.
36. or/17-35
37. (9 and 16 and 36)
[Psychotherapies]
38. exp PSYCHOTHERAPY/
39. exp PSYCHOTHERAPEUTIC TECHNIQUES/
40. exp COGNITIVE TECHNIQUES/
41. exp COUNSELING/
42. 3300.cc. [Classification Code: Health & Mental Health Treatment & Prevention]
43. 3310.cc. [Classification Code: Psychotherapy & Psychotherapeutic Counseling]
44. 3311.cc. [Classification Code: Cognitive Therapies]
45. 3312.cc. [Classification Code: Behavior Therapy & Behavior Modification]
46. 3313.cc. [Classification Code: Group & Family Therapy]
47. 3314.cc. [Classification Code: Interpersonal & Client Centered & Humanistic Therapy]
48. 3315.cc. [Classification Code: Psychoanalytic Therapy]
49. (CBT or c-CBT or iCBT or coping skills or counsel?ing or mindfulness or psychoanal* or psychotherap* or rehabilitat*).ti,ab,id.
50. ((psychologic* or psychodynamic or behavio?r or cognitive) adj3 (intervent* or therap* or treat* or manag*)).ti,ab,id.
51. (Abreaction or Acting Out or Adlerian or Adolescent Psychotherap* or Age Regression or Analytical Psychotherap* or Anger Control
or Anger Management or Art Therap* or Assertive* Training or Autogenic Training or Autosuggestion or Aversion Therap* or Balint
Group or Behavio?r Contracting or Behavio?r Modification or Behavio?r Therap* or Bibliotherap* or Biofeedback or Body Psychotherap*
or Brief Psychotherap* or Caregiver Support or Child Psychotherap* or Client Cent* Therapy or Cognitive Behavio?r Therap* or
Cognitive Behavio?ral Stress Management or Cognitive Rehabilitation or Cognitive Restructuring or Cognitive Therap* or Colo?r
Therap* or Conjoint Therap* or Contingency Management or Conversion Therap* or Conversational Therap* or Countertransference
or Couples Therap* or Covert Sensitization or Crisis Intervention).ti,ab,id,de.
52. (Dance Therap* or Dialectical Behavio?r Therap* or (Dream* adj3 Analys*) or Eclectic Psychotherap* or Eclectic Therap* or
Emotion* Focus* Therap* or Emotional Freedom Technique or Encounter Group Therap* or Existential Therap* or Experiential Psy-
chotherap* or Exposure Therap* or Expressive Psychotherap* or Eye Movement Desensiti#ation or Family Therap* or Free Association
or Geriatric Psychotherap* or Gestalt Therap* or Griefwork or Group Psychotherap* or Group Therap* or Guided Image* or Holistic
Psychotherap* or Humanistic Psychotherap* or Hypnosis or Hypnotherapy or Hypnoti#zability or Implosive Therap* or Individual
Psychotherap* or Insight Therap* or Integrative Psychotherap* or Integrative Therap* or Interpersonal Psychotherap*).ti,ab,id,de.
53. (Logotherap* or Marathon Group Therap* or Marital Therap* or Meditation or Mental Healing or Metacognitive Therap* or
Milieu Therap* or Mind train* or Morita Therap* or Music Therap* or Narrative Therap* or Nondirective Therap* or Personal
Construct Therap* or Person Cent* Therap* or Persuasion Therap* or Pet Therap* or Play Therap* or Primal Therap* or Problem
Solving Therap* or Psychoanalysis or Psychoanalytic Therap* or Psychodrama or Psychodynamic Psychotherapy or Psychotherapeutic
Counsel* or Psychotherapeutic Processes or Psychotherapeutic Training or (Psychotherap* adj3 Rational-Emotive)) .ti,ab,id,de.
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54. (Rational Emotive Behavio?r Therap* or Reality Therap* or Reciprocal Inhibition Therap* or Relationship Therap* or Relaxation
Stress Management or Relaxation Technique* or Relaxation Therap* or Relaxation Training or Reminiscence Therap* or Role Playing or
Self Analys* or Self Esteem Building or Sensitivity Training Group* or Sex Therap* or Sleep Phase Chronotherap* or Socioenvironmental
Therap* or Sociotherap* or Solution Focused Therap* or Support Group* or (Support adj3 Psycho*) or Systematic Desensiti#ation or
Therapeutic Communit* or Transactional Analysis or Validation Therap*).ti,ab,id,de.
55. or/38-54
[Antidepressants]
56. PSYCHOPHARMACOLOGY/ or NEUROPSYCHOPHARMACOLOGY/
57. 3340.cc. [Classification Code: Clinical Psychopharmacology]
58. exp ANTIDEPRESSANT DRUGS/
59. NEUROTRANSMITTER UPTAKE INHIBITORS/ or exp SEROTONIN NOREPINEPHERINE REUPTAKE INHIBITORS/
or exp SEROTONIN REUPTAKE INHIBITORS/
60. exp MONOAMINE OXIDASE INHIBITORS/
61. exp TRICYCLIC ANTIDEPRESSANT DRUGS/
62. (antidepress* or anti depress* or MAOI* or monoamine oxidase inhibit* or ((serotonin or norepinephrine or noradrenaline or
nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or
antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*).ti,ab,id,de.
63. (Agomelatine or Alnespirone or Amoxapine or Amfebutamone or Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide
or Amoxapine or (Atomoxetine or Tomoxetine) or Benactyzine or Brofaromine or Bupropion or Butriptylin* or Cianopramine or
Cilobamine or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or Clovoxam-
ine or (CX157 or Tyrima) or Dapoxetine or Deanol or Dibenzepin* or Demexiptilin* or Deprenyl or Desipramine or Desvenlafaxine
or Dibenzepin or Dimetacrin* or (Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS-233 or Enilospirone or Eptapirone or
Escitalopram or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluparoxan or Furazolidone or Fluvoxamine or Harmaline
or Harmine or Hyperforin or Hypericum or John* Wort or Idazoxan or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or
Imipraminoxide or Isocarboxazid* or Lesopitron or Levomilnacipran or Lithium or Lofepramin* or (Lu AA21004 or Vortioxetine) or
Lu AA24530 or LY2216684 or Maprotiline or Medifoxamine or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine
or Mirtazapine or Moclobemide or Nefazodone or Nialamide or Nitroxazepine or Nomifensine or Norfenfluramine or Nortriptyline
or Noxiptilin* or Opipramol or Oxaflozane or Paroxetine or Phenelzine or Pheniprazine or Pipofezin* or Pirandamine or Piribedil or
Pirlindole or Pivagabine or Pizotyline or Propizepine or (Protriptylin* or Pertofrane) or Quinupramine or Quipazine or Reboxetine
or Ritanserin or Rolipram or Scopolamine or Selegiline or Sertraline or (Setiptiline or Teciptiline) or Tandospirone or Tetrindole or
Thiazesim or Thozalinone or Tianeptin* or Toloxatone or Tranylcypromine or Trazodone or Trimipramine or 5-Hydroxytryptophan
or 5-HT or Tryptophan or Hydroxytryptophan or Venlafaxine or Viloxazine or Vilazodone or Viqualine or Zalospirone or Zimeldine
or (Alaproclate or Caroxazone or Diclofensine or Fenfluramine)) .ti,ab,id,de.
64. or/56-63
[Mood Stabilisers or Antipsychotics]
65. MOOD STABILIZERS/
66. exp ANTICONVULSIVE DRUGS/
67. exp NEUROLEPTIC DRUGS/
68. ((mood stabili?er*1 or lithium or eslicarbazepine or licarbazepine or valnoctamide or carbamazepine or valproate or valproic acid
or divalpro* or ziprasidone or gabapentin or lamotrigine or topiramate) or (antipsychotic*1 or amisulpride or aripiprazole or asenapine
or cariprazine or clozapine or haloperidol or iloperidone or lurasidone or olanzapine or quetiapin* or paliperidone or prosulpride or
risperidone)).ti,ab,id,de.
69. or/65-68
70. (9 and (55 or 64 or 69) and 36)
71. 37 or 68 (c3000 hits)
OVID cross-search
1. MAINTENANCE THERAPY/
2. (continuation or maintenance).ti.
3. ((continuation or maintenance) adj2 (efficacy or effectiveness or medicat* or pharmacotherap* or phase or study or therap* or
psychotherap* or treatment*)).ti,ab,id,kf,kw.
4. ((continu* or maint*) adj (medicat* or pharmacotherap* or therap* or psychotherap* or treatment*)).ti,ab,id,kf,kw.
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8. DYSTHYMIC DISORDER/ or DYSTHYMIA/
9. dysthymi*.ti,ab,id,kf,kw.
10. MAJOR DEPRESSION/ or DEPRESSIVE DISORDER/ or DEPRESSIVE DISORDER, MAJOR/
11. “CHRONICITY (DISORDERS)”/ or CHRONIC ILLNESS/ or CHRONIC DISEASE/ or RECURRENCE/ or RECURRENT
DISEASE/ or RECURRENCE RISK/ or REMISSION/
12. (10 and 11)
13. RECURRENT DEPRESSION/
14. (depress* adj2 recurr*).ti,ab,id,kf,kw.
15. persistent depressive disorder.ti,ab,id,kf,kw.
16. (6 or 7 or 8 or 9 or 12 or 13 or 14 or 15)
17. (5 and 16)
[De-duplicated = 1400]
Cochrane Central Register of Controlled Trials (CENTRAL)
#1 (continuation or maintenance):ti
#2 ((continuation or maintenance) near/3 (efficacy or effectiveness or medicat* or pharmacotherap* or phase or study or therap* or
psychotherap* or treatment*))
#3 ((continu* or maint*) next (medicat* or pharmacotherap* or therap* or psychotherap* or treatment*))
#4 (#1 or #2 or #3)
#5 “chronic* depress*”
#6 “doubl* depress*”
#7 MeSH descriptor: [DYSTHYMIC DISORDER] this term only
#8 dysthymi*
#9 MeSH descriptor: [DEPRESSIVE DISORDER] this term only
#10 MeSH descriptor: [DEPRESSIVE DISORDER, MAJOR] this term only
#11 MeSH descriptor: [CHRONIC DISEASE] explode all trees
#12 MeSH descriptor: [RECURRENCER] this term only
#13 (#9 or #10) and (#11 or #12)
#14 (depress* near/3 recurr*)
#15 (persistent next depress*)
#16 (#5 or #6 or #7 or #8 or #13 or #14 or #15)
#17 (#4 and #16)
H I S T O R Y
Protocol first published: Issue 11, 2017
Date Event Description
17 June 2016 Feedback has been incorporated Feedback of editors incorporated
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